LENZ THERAPEUTICS INC (LENZ) Stock News

NASDAQ:LENZ - US52635N1037 - Common Stock

38.2 USD

+0.83 (+2.22%)

Last: 8/28/2025, 8:22:52 PM

37.98 USD

-0.22 (-0.58%)

After Hours: 8/28/2025, 8:22:52 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

LENZ Latest News, Press Relases and Analysis

All

Press Releases

4 days ago - By: LENZ Therapeutics, Inc.

LENZ Therapeutics to Present at Upcoming Investor and Medical Conferences

18 days ago - By: Benzinga - Mentions: OMI SLRX REPL XCUR ...

12 Health Care Stocks Moving In Monday's Pre-Market Session

18 days ago - By: Benzinga - Mentions: WLGS PAPL ORIS MRM ...

Why International Money Express Shares Are Trading Higher By Around 54%; Here Are 20 Stocks Moving Premarket

a month ago - By: LENZ Therapeutics, Inc.

LENZ Therapeutics Announces US FDA Approval of VIZZ™ for the Treatment of Presbyopia

a month ago - By: The Motley Fool

Lenz (LENZ) Q2 Revenue Jumps 604%

a month ago - By: LENZ Therapeutics, Inc.

LENZ Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

a month ago - By: LENZ Therapeutics, Inc.

LENZ Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

a month ago - By: LENZ Therapeutics, Inc.

LENZ Therapeutics Announces NMPA Submission of New Drug Application for LNZ100 in China for the Treatment of Presbyopia

a month ago - By: Zacks Investment Research

LENZ Therapeutics, Inc. (LENZ) is a Great Momentum Stock: Should You Buy?

2 months ago - By: LENZ Therapeutics, Inc.

LENZ Therapeutics and Laboratoires Théa Announce Exclusive License and Commercialization Agreement for LNZ100 in Canada

3 months ago - By: LENZ Therapeutics, Inc.

LENZ Therapeutics to Present at Upcoming Investor Conferences

4 months ago - By: LENZ Therapeutics, Inc.

LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia

4 months ago - By: LENZ Therapeutics, Inc.

LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia

4 months ago - By: LENZ Therapeutics, Inc.

LENZ Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

4 months ago - By: LENZ Therapeutics, Inc.

LENZ Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

4 months ago - By: LENZ Therapeutics, Inc.

LENZ Therapeutics to Participate in Upcoming BofA Securities 2025 Health Care Conference

4 months ago - By: LENZ Therapeutics, Inc.

LENZ Therapeutics to Participate in Upcoming BofA Securities 2025 Health Care Conference

4 months ago - By: LENZ Therapeutics, Inc.

LENZ Therapeutics to Report First Quarter 2025 Financial Results and Recent Corporate Highlights on May 7th, 2025

4 months ago - By: LENZ Therapeutics, Inc.

LENZ Therapeutics to Report First Quarter 2025 Financial Results and Recent Corporate Highlights on May 7th, 2025

5 months ago - By: Climb Bio, Inc. - Mentions: CLYM ABOS SLDB VERV

Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

5 months ago - By: LENZ Therapeutics, Inc.

LENZ Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

5 months ago - By: LENZ Therapeutics, Inc.

LENZ Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

6 months ago - By: LENZ Therapeutics, Inc.

LENZ Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights on March 19, 2025

6 months ago - By: LENZ Therapeutics, Inc.

LENZ Therapeutics to Host Commercial Day on April 15, 2025

6 months ago - By: LENZ Therapeutics, Inc.

LENZ Therapeutics to Participate in Upcoming Investor Conferences

6 months ago - By: LENZ Therapeutics, Inc.

LENZ Therapeutics to Participate in Upcoming Investor Conferences